Indeed, PRMT5 is overexpressed in several cancers including melanoma, multiple myeloma, glioblastoma, lung, bladder urothelial, gastric, ovarian, and colorectal cancers, and PRMT5 expression correlates with poor patient prognosis [7,10,11,12,13,14,15,16,17,18,19]. This evidence concerns the gene PRMT5 and plasma cell myeloma.